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We have recently demonstrated that heme oxygenase is expressed in both healing 
wounds and in pressure ulcers.  Heme oxygenase has been shown to have important 
cytoprotective functions in myocardial ischemia-reperfusion injury and organ allograft 
survival.  The cytoprotective effects of heme oxygenase are multifactorial.  Besides 
reducing levels of pro-oxidant heme, heme oxygenase products (bilirubin, carbon 
monoxide, and iron) have been demonstrated to possess anti-oxidant, anti-inflammatory, 
anti-apoptotic, and anti-proliferative properties.  These properties make heme oxygenase 
xi 
an attractive therapeutic target for the prevention and treatment of chronic wounds.  The 
purpose of this study was two-fold: evaluate the effects of carbon monoxide (CO) on the 
expression of heme oxygenase (HO-1) in dermal fibroblasts, and determine and begin to 
investigate the mechanisms responsible for CO-induction of HO-1.  The ability of a 
second-generation carbon monoxide donating molecule-tricarbonyldichlororuthenium (II) 
dimer (CORM-2) to induce HO-1 protein expression in dermal fibroblasts was examined.  
Western blotting techniques were utilized to determine HO-1 expression.  CORM-2 (100-
300uM) induced maximum expression of HO-1.  The maximum response to CORM-2 
occurred between 12 and 20 hours.  Inhibition of MAPK, PI3-K, JNK pathways showed no 
changes in HO-1 expression.  Likewise inhibition of cGMP, a known pathway for CO, had 
no effect on protein expression suggesting that HO-1 expression by CORM-2 works by an 
alternate pathway.  In conclusion the ability of CO, a product of heme degradation, to 
induce HO-1 in dermal fibroblasts may serve as a mechanism to amplify HO-1 expression 
in stressed tissues and may serve as the basis for a novel therapeutic approach for treating 
chronic wounds.    
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Introduction 
 
General Purpose 
Due to their complexity and multifactoral nature, little is known about chronic 
wounds and the mechanisms involved in their development.  Therefore current research 
strategies have attempted to target various aspects of wound repair in an attempt to gain a 
better understanding of the pathophysiology behind chronic wounds.  One objective of this 
laboratory is to determine the initiation events involved in the formation of chronic wounds 
in an attempt to provide better insight for the prevention and treatment of these wounds. 
 
Specific Aim #1:  To determine if CO released from CORM-2 will alter expression of HO-
1 in human dermal fibroblasts 
 
Specific Aim #2:  To investigate the underlying mechanism responsible for CO induction 
of HO-1 by CORM-2 in human dermal fibroblasts by identifying involved signaling 
pathways.  This was accomplished through the use of specific inhibitor pathways.   
 
Hypothesis:  We predicted that the carbon monoxide released from CORM-2 will inhibit 
heme oxygenase expression and that the mechanism would involve the cGMP pathway.   
 
2 
Background 
 
 Chronic skin wounds are characterized by the slow or non-healing breakdown of 
epidermal and dermal tissue.  Every year millions of people experience chronic wounds.26   
Care of these individuals is a significant problem that will continue to grow as our 
population ages.  Effective wound treatment requires carefully considered interventions 
often requiring multiple clinic or hospital visits which results in a significant drain on our 
health system in terms of nursing time, costs, as well as physical and emotional strain to 
the individual patient.14   The resulting costs of wound care are staggering and more 
efficacious and cost-effective therapies are needed to decrease this burden.  
 The majority of chronic skin wounds are found in the lower extremities and are 
predominantly due to vascular, pressure, or neuropathic (diabetic) etiology.33  The 
principle population for chronic wounds is Caucasian women above the age of 65. Other 
factors such as immobility, nutrition, and underlying pathogenesis (e.g. chronic venous 
insufficiency and diabetes) can contribute and sometimes delay the healing process.26  
Little is known about chronic wounds and the mechanisms involved in their development.  
Treatments for these wounds include allografts, vacuum-closure, as well as an assortment 
of topical agents and dressings.12,29 Although current treatment modalities attempt to cure 
these wounds, methods to reverse the damage have proven to have modest effectiveness. 
The largest obstacle is the wound tissue’s complex and multifactoral healing nature.  This 
characteristic has given researchers great difficulty in pinpointing the root cause for the 
development and persistence of these wounds.  The unique nature of each individual 
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wound compounds the problem of analysis and investigation.  Research efforts attempting 
to examine wound pathophysiology have been hampered by the lack of an adequate 
chronic wound healing model, and the complexity of the pathophysiologic wound healing 
cascade has limited attempts at pharmacological modification.28  Therefore current 
research strategies have attempted to target various aspects of wound repair in an attempt 
to gain a better understanding of the pathophysiology behind chronic wounds.   
 
Normal Wound Repair 
 
 Normal wound repair and regeneration is a sophisticated and highly organized 
process composed of well-orchestrated interactions between a multitude of cells, chemical 
pathways, and associated molecules.  Individual wounds are unique; however, the steps 
involved in the healing process remain the same with an end goal that results in an efficient 
and predictable repair process.  The entire process involves three phases or stages and can 
last from several days up to a year.  Although the process is separated into individual 
phases, there is great overlap between them.48  The process of wound healing is very 
dynamic and although the normal wound undergoes all of the phases, different parts of the 
wound may be at different stages due to different healing rates.   
 During the first phase there is hemostasis and inflammation of the wounded area.  
After the initial cut or tear in the skin, the body's priority is to stop the bleeding.  This is 
accomplished by the constriction of the injured endothelial cells and activation of nearby 
platelets to form a clot.  The clot itself is composed of platelets, fibrin, and fibronectin, 
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which serve not only to attenuate bleeding but to also act as the structure upon which 
migrating cells will adhere.  The clot also serves to concentrate the elaborated cytokines 
and growth factors.4,23  Once activated, platelets begin to secret a variety of growth factors, 
cytokines, and inflammatory factors such as histamine which serve to increase blood flow 
and trigger the migration of cells to the damaged area.7  The increased vasodilatation from 
the buildup of cells and inflammatory factors allows for increased cellular traffic to the 
area of injury.  Polymorphonucleocytes (PMNs) are the primary cells that first begin to 
migrate to the damaged area and enter the tissue.  They are signaled to the site by 
molecules such as fibronectin, growth factors, and neuropeptides.16  PMNs primary 
function is to phagocytize dead and injured cells around the wound.  They also secrete an 
assortment of proteases that help with this function as well as to breakdown damaged 
components of the extracellular matrix (ECM).  These necessary processes facilitate the 
fabrication/production of new extracellular matrix material.  As neutrophils phagocytize 
material, reactive oxygen species (ROS) are released as a by-product of their metabolism.  
ROS play an important role in the wound by killing invading bacteria.  After 
approximately 1-2 days neutrophils die off and are replaced by vast numbers of 
monocytes.  Once in the tissue, monocytes differentiate into macrophages and continue to 
phagocytize debris, bacteria, as well as dying neutrophils. They also trigger the release of 
matrix metalloproteases (MMPs) from cells which aid in the digestion of the ECM.4 
Macrophages are stimulated by the low oxygen content of their surroundings to produce 
factors such as vascular endothelial growth factor (VEGF), and platelet-derived growth 
factor (PDGF) which induce and speed angiogenesis.5     Macrophages also secrete a 
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multitude of other chemical stimulants that cause cells to reepithelialize the wound, create 
granulation tissue, and lay down a new extracellular matrix.  4,7  Stimulated fibroblasts 
signal keratinocytes to migrate and proliferate.  The now degraded ECM is replaced by 
collagen, proteoglycans, and fibronectin.  Neutrophil and macrophage numbers begin to 
decrease, signaling the end of the inflammation phase and the start of the proliferation 
phase.   
The proliferation phase is characterized by matrix formation, proliferation of 
fibroblasts, and increased migration of endothelial cells.  Fibroblast and endothelial cells 
are the dominant cells during this phase. Epithelialization occurs soon after the initial 
injury.  This proliferation is triggered by EGF and TGF-α released from platelets and 
macrophages.17  Fibroblasts stimulated by TGF-β produce and begin secreting fibrin, 
fibronectin, collagen, as well as other molecules to form the new ECM.  This newly 
formed ECM will also act as a lattice upon which cells can adhere.  TGF- β causes 
fibroblasts to differentiate into myofibroblasts which aid in wound contraction.10  As 
collagen and other components of the ECM are laid down, the final phase of wound repair 
begins.   
The last phase, maturation and remodeling, is characterized by the depositing of 
collagen in such a fashion as to make an organized matrix.  This matrix continues to 
become thicker and stronger as more collagen is deposited.  During this time levels of 
MMPs as well as other proteases, that were once utilized to breakdown the previous 
matrix, are decreasing.  Abnormalities in this last phase can result in clinical disorders such 
as the development of keloids or hypertrophic scars.4,53  In the later stages of healing, the 
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high density of capillaries, myofibroblasts and the hypertrophic epidermal layer undergo 
apoptosis (programmed cell death), effectively thinning the tissue and returning it to a 
normal appearance.4,7,9 
 
Impaired Wound Healing 
 
 
Normal wound repair is an organized and predictable process that involves a 
precise balance between the breakdown of damaged tissue and production of new tissue 
that results in the timely healing of the wound. For one reason or another, nonhealing 
chronic wounds have lost this balance and organization and are detained in one or more of 
the wound healing stages.  These wounds may take months, years, or never heal at all.  
There are various types of chronic wounds each with unique characteristics.  The majority 
of chronic wounds can be classified into three categories composed of: pressure ulcers, 
venous ulcers, and diabetic foot ulcers.26  
Accounting for more than 70 to 80% of all cases, venous ulcers are the most 
prevalent type of chronic wound.  There are approximately 600,000 reported cases each 
year in the US alone.15,26 Although the precise etiology of these wounds is not known, 
these ulcers occur almost exclusively in association with chronic venous insufficiency 
(CVI) in the lower extremities, where they are characterized by substantial and prolonged 
venous hypertension.36 Venous hypertension is most often a result of damaged or non-
functioning valves that fail to prevent the backflow of blood.  This pooling of the blood at 
high pressure in the lower-extremities leads to of tissue hypoxia, necrosis, and ultimately 
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ulceration.  Other condition such as cutaneous arteriovenous fistulas, thrombosis, and 
leukocyte-plugging can compound the problem by further depriving the already hypoxic 
skin.35,38,54  Research has also demonstrated that hypertension, circulatory stasis, and 
blood-shearing forces can trigger an increased inflammatory response, which is thought to 
contribute to ulcer development.38  Compression therapy is utilized to encourage the flow 
of nutrients as well as to prevent venous stasis, edema, and blood clot formation. 
Pressure ulcers constitute another important class of chronic wounds.  Localized 
damage to the skin and underlying tissue from pressure, shear, or frictional forces result in 
the formation of these wounds. Typically 95% of these lesions occur in the lower 
extremities in which tissue over a bony prominence such as the sacrum or the heel is thin 
and hypoxia is more likely to occur.50  The majority of these wounds are found in elderly 
patients (>65) and are associated with co-morbid conditions such as poor nutrition and 
immobility.26  These wounds are readily observed in hospitals and nursing homes where 
patient mobility might be a challenge.  Prolonged pressure to a site leads to the occlusion 
of capillary and lymphatic vessels which impedes the flow of blood and lymph resulting in 
tissue ischemia.  Eventually, these changes coupled with reperfusion injury lead to necrosis 
of the underlying muscle, tissue, dermis and epidermis.50  If no corrective action is taken, 
tissue pressure can reach 200mmHg expediting ulcer formation.11  Prevention and 
treatment of these wounds is difficult, and once wounds form , they are a clinical challenge 
to treat. This is especially true in paralyzed and other immobile patients.  Pressure wounds 
take time to develop. By the time external symptoms are noted, severe underlying tissue 
damage has already occurred.  
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The third and final class of chronic wounds is the diabetic foot ulcer.  The 
incidence of this class of wound has increased as the prevalence of diabetes has risen over 
that past decade.  Diabetic foot problems occur in both type 1 and type 2 diabetes and are 
most common in men (>65).14,41  Like pressure ulcers, diabetic ulcers usually occur around 
the heel region of the foot and can be a result of prolonged pressure.  Infection has been 
one of the major obstacles in treatment of these wounds.  If not treated immediately 
infection can result in the amputation of the limb and sometimes death.  Chronic foot 
ulceration is the leading cause of amputation in the elderly patient population,39 with 
diabetics having a 15-fold higher incidence of amputation compared to nondiabetics.32 
Neuropathy associated with diabetes also affects detection and treatment. With a higher 
threshold of pain and sensation, these patients become unaware of ischemic pain and 
pressure ulcer formation.  Both this reduced perception of pain and sensation combined 
with an already weakened immune system increases the risk of infection.  As the disease 
progresses a weakened immune system can also cause damage to small blood vessels, 
preventing adequate oxygenation of tissue, which can exacerbate chronic wounds.30 
Immobility, structural deformity, and peripheral vascular diseases associated with diabetes 
all lead to ulcer formation.  Due to the many disease conditions and problems associated 
with diabetes, there is great difficulty in the prevention and treatment of these wounds. 
 
Common Factors 
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Research has had little success in determining the etiology of chronic wounds.  The 
multifactoral nature coupled with the uniqueness of each individual wound has proven to 
be a major obstacle.  Although each class of chronic wounds appears to have little in 
common, there are some similarities between the groups.  Age, tissue hypoxia, ischemia-
reperfusion injury, and bacterial colonization all seem to be major players in the wound 
formation and maintenance.  As noted, the majority of chronic wounds occur in elderly 
patients over the age of 65.34  Cells in the local environment of a chronic wound are subject 
to significant stresses, including chronic inflammation, the harmful presence of reactive 
oxygen species, ischemia-reperfusion injury, as well as an increase of various proteases in 
their environment.  These stresses act to prolong healing time and have been shown to alter 
gene expression.  Studies have shown that in addition to these stresses, aged patients also 
have an increased rate of cell senescence and a decreased proliferative capacity.33  As 
mentioned above other factors such as immobility, impaired or weakened immune systems 
as well as a number of other diseases common among elderly contribute to wound 
development and risk of infection thus decreasing the body’s ability to heal efficiently.   
Adequate perfusion of the skin and tissue is very important for normal wound 
healing.  Tissue oxygenation is regulated by blood flow which is in turn controlled by 
arterial flow, arteriovenous gradients, capillary density, and local tissue metabolism.34  
Lack of sufficient oxygen supply to the site is predominantly due to edema.  By increasing 
actual tissue pressure and the distance between tissue and capillaries, edema reduces the 
diffusion of oxygen resulting in a hypoxic state.  Edema is readily found in diabetic foot 
ulcers as well as pressure and venous ulcers although not as common.38,41 
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Another similarity is the invasion of bacteria into the injured area.  Within 48 hours 
of injury, bacteria from the surrounding skin invade the site resulting in a baseline level of 
bacteria.3  Inflammation is triggered as the immune system responds to the invading 
bacteria thereby adding stress to an already compromised environment.  Protease levels 
and inflammatory molecules increase as the number of migrating neutrophils rise.  These 
proteases begin to degrade growth factors and parts of the ECM necessary for proper 
healing.  The type and amount of bacteria also seem to be important in wound 
development and maintenance.  Skin grafts performed on wounds with bacterial counts in 
excess of 100,000/mm3 have had little success.42  Treatments such as vacuum-assisted 
closure have had moderate success partly because it is believed that it reduces the bacterial 
count.3,42 
Ischemia-reperfusion injury (I/R) is the last factor associated with all three classes 
of chronic wounds.  Although the etiology of each type of chronic wound is difficult to 
pinpoint, recent research hypothesis’ that I/R injury is the key event common in the 
formation of all three types of wounds.33,40 I/R injury has also been linked in the 
pathophysiology of other diseases such as myocardial infarction, cerebral ischemia, stroke, 
hemorrhagic shock, and organ transplantation.1  
I/R injury occurs when blood supply to tissue is interrupted resulting in ischemia 
thereby damaging metabolically active tissue.  Restoration of blood flow to the ischemic 
area initiates a cascade of events that can act to potentiate cell injury.  In venous stasis 
ulcers, the lack of an arterial-venous pressure gradient results in the pooling of blood in the 
lower extremities.  This blood stasis prevents the flow of nutrients and oxygen to 
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surrounding tissue and eventually leads to ischemic injury.   When the leg is elevated or 
moved, flow is restored resulting in reperfusion injury.  In diabetic ulcers and pressure 
wounds ischemia result from pressure on the tissue over protruding bony areas such as the 
heal or sacral area.  When the pressure is removed reperfusion injury occurs.34   The 
repetitive nature of I/R injury makes it so damaging.  Each cycle acts to further injure the 
already damage area and will eventually cause tissue necrosis and ulcer formation. 
Inflammation and reactive oxygen species (ROS) are the key mechanisms 
responsible for the damaging affects of I/R injury.   As ischemia in tissue intensifies, lack 
of oxygen and vital nutrients dramatically alter the ability of cells to perform aerobic 
metabolism.  As a result surrounding tissue reduces its metabolism in order to maintain 
function and soon glycolysis becomes the predominant source of ATP.21   Anaerobic 
metabolism results in a dramatic decrease in ATP levels and the cell cannot sustain the 
transmembrane potential across the plasma membrane.  Disruption of this potential results 
in the influx of various ions (mainly Na+), which cause the cell to swell.  ATP-independent 
pumps such as the Na+/Ca2+ exchanger are activated to help reestablish normal ion 
concentrations and to prevent cell lysis.  Intracellular Ca2+ levels rise and trigger pathways 
that lead to membrane breakdown as well as activation of reactive oxygen species.24,51   
Ischemia also induces the expression of endothelial adhesion molecules and 
cytokines that serve to create a pro-inflammatory environment.   As ischemia ends and 
reperfusion begins, leukocytes migrate into the ischemic area and attach themselves to the 
wall of the endothelium as well as to each other.  These interactions are mediated through a 
series of glycoproteins, mainly selectins and integrins.  Once attached, the leukocytes 
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begin to interact with the inflammatory cytokines and mediators already produced by the 
ROS to form tight interactions with the endothelium.  Mediated by cell adhesion molecules 
(like P-selectin, L-selectin, PAF, E-selectin, IL-8, VCAM, and B2-integrins), leukocytes 
start their migration into the tissue.45   Once in the tissue leukocytes such as PMNs and 
macrophages cause damage by secreting proteases as well as producing large amounts of 
ROS and may even obstruct surrounding microcirculation further contributing to an 
already ischemic environment.19  A decrease in nitric oxide (NO) is also associated with 
I/R injury.  Less nitric oxide significantly impairs reperfusion and is responsible for 
signaling the increased production of proteases and pro-inflammatory cytokines.20 
Reactive oxygen species (ROS) describes oxygen free radicals such as superoxide 
(O2-), hydroxyl radical (OH-) as well as nonradical oxygen species like hydrogen peroxide 
(H2O2).  In moderate concentrations, these species play an important role in the wound 
healing process serving as cellular messengers.19  However in excess, these species can 
have a variety of harmful effects on both the cellular and tissue level. The majority of 
reactive oxygen species are produced by neutrophils during the ‘respiratory burst’ phase of 
inflammation, however macrophages, fibroblasts, and endothelial cells produce them as 
well.56  ROS can have a wide variety of damaging effects on proteins, membrane lipids, 
and nucleic acid in DNA.  Oxidation of proteins is primarily through the hydroxyl radical 
and most readily affects sulfhydryl groups. This modification can alter protein structure 
and function and can lead to increased proteolytic turnover.19  Changes in the proteolytic 
environment can result in defective or insufficient ECM formation leading to prolonged 
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healing.  Not only do ROS play a significant role in chronic wounds but they also have 
been implicated in other skin diseases, including skin cancer and psoriasis.31 
 
Heme Oxygenase 
 
As local tissue undergoes repeated bouts of ischemia followed by reperfusion, red 
blood cells and tissue begin to breakdown.  One consequence of RBC destruction is the 
release of heme into the bloodstream.  Free heme can interact with oxygen to produce 
cytotoxic ROS, which can ultimately cause DNA damage, lipid peroxidation, and protein 
degradation.22  The body counteracts the harmful effects of free heme by producing the 
enzyme heme oxygenase.   
Heme oxygenase catalyzes the first and rate-limiting step in the oxidative 
degradation of heme to carbon monoxide, biliverdin, and free iron (Fe2+) (Figure 1).  
Researchers have characterized two main isoforms of heme oxygenase; an inducible 
isoform, heme oxygenase-1 (HO-1), and a constitutively expressed isoform, heme 
oxygenase-2 (HO-2).  Recently there has also been some debate over a third possible 
isoform.25  The two main isoforms catalyze the same reaction and are very similar in 
structure, sharing a 43% amino acid homology.  Both HO-1 and HO-2 also have similar 
enzyme kinetics with HO-1 having a slightly greater affinity for the heme molecule.43   
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Figure 1:  Heme oxygenase and its byproducts: biliverdin, bilirubin, Fe2+, and CO. 
Ryter, S. W. et al. Physiol. Rev. 86: 583-650 2006; doi:10.1152/physrev.00011. 
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HO-1 (~32 kDa), the main isoform, is omnipresent throughout the body with higher 
concentrations located in areas with high RBC and hemoglobin turnover including the 
spleen, liver, kidney, and bone marrow.  Subcellularly, HO-1 is distributed in the 
endoplasmic reticulum, nucleus, and plasma membrane.  HO-2 (~36 kDa) is distributed in 
the liver, spleen, brain and testes with similar subcellular locations as HO-1.37,43 
Originally discovered and categorized as a class of heat shock proteins (Hsp32), 
heme oxygenase functions in the protection against cellular stresses.  Unlike HO-2, which 
is constituently expressed, the inducible form of heme oxygenase (HO-1) remains at 
relatively undetectable levels until expression is triggered by cellular stresses.43  HO-1 
responds to a multitude of chemical and physical stressors including hypoxia, ROS, UV 
irradiation, quinones, nitric oxide, heavy metals, cytokines (TNF-α, interleukins, TGF-β), 
lipopolysaccharide and, organic chemicals (e.g. sodium arsenite).2,8  Multiple factors are 
responsible for the induction of heme oxygenase underlying its importance as a protective 
mechanism throughout the body. 
The cytoprotective effects of heme oxygenase are multifactoral.  Besides reducing 
levels of pro-oxidant heme, HO-1 products (bilirubin, carbon monoxide, and iron) have 
been demonstrated to possess anti-oxidant, anti-inflammatory, and anti-apoptotic 
properties.43  Iron (Fe2+) is one of the first of three products resulting from the catabolism 
of heme.  Most of the cytoprotection afforded by Fe2+ is believed to be linked to its ability 
to increase the expression of the protein ferritin.  Ferritin primarily functions in the 
maintenance of normal concentrations of cellular iron. In vitro experiments have also 
determined that iron helps to maintain intracellular iron concentrations through the 
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activation of a series of ATP-dependent iron pumps.  By binding iron, ferritin also prevents 
free iron from stimulating reactive oxygen species formation.     
Biliverdin is another product formed from the breakdown of heme.  Almost 
immediately after formation biliverdin is converted to bilirubin by the enzyme biliverdin 
reductase.  Both biliverdin and bilirubin have been demonstrated to possess anti-oxidant 
effects.43  In vitro experiments have demonstrated bilirubin’s ability to prevent the 
photoxidation of hydrocarbons by complexing with singlet molecular oxygen.  Other 
studies have shown that bilirubin protects cells by neutralizing harmful agents such as 
hypochlorous acid released from macrophages.37,43   
Once thought of as deleterious or at best as waste, carbon monoxide has recently 
attracted interest by its beneficial effects.  Like oxygen, carbon monoxide has the ability to 
reversibly bind to hemoglobin and myoglobin.  With an affinity approximately 240 times 
that of oxygen, carbon monoxide preferentially binds to the active sites of hemoglobin.43   
Carbon monoxide concentrations above physiological levels will result in hypoxia and 
destruction of oxygen sensitive vital organs including the brain and lungs.  If levels remain 
high, CO poisoning will eventually lead to respiratory distress and death.  In contrast to 
high levels of CO, lower levels have been demonstrated to possess cytoprotective effects.  
One of the major effects of CO is its role in inflammation.  Carbon monoxide prevents the 
activation and aggregation of platelets; thereby reducing the ability of platelets to produce 
and release pro-inflammatory signals.  Another protective function of CO is its ability to 
inhibit apoptosis in certain cells including endothelial, fibroblasts, hepatocytes, and β-cells 
of the pancreas.18,37,43   
17 
HO-1 derived CO apparently operates through multiple pathways, each unique to 
different types of cells.  The two main pathways identified to date, involve the activation of 
the mitogen activated protein kinases (MAPK) and cyclic guanylyl cyclase (cGMP) 
systems.    Carbon monoxide can bind directly with soluble guanylyl cyclase (sGC) 
thereby stimulating the production of cGMP.  Cyclic GMP can then directly perform its 
effects on the target cells.  Treatment with YC-1 (a sGC agonist) increases the sensitivity 
of sGC stimulation by CO.43  In contrast, signaling of p38 MAPK by CO is not as direct as 
the cGMP pathway.  The MAPK pathway represents the downstream target rather than the 
direct binding target for CO.44  The primary binding target of CO for activation of this 
pathway is unknown and may differ for each cell type.  The target for CO may also involve 
several different molecules.  Other potential targets of CO include proteins in which heme 
acts as a prosthetic group (e.g. hemoglobin, myoglobin, sGC, cyclooxygenase, cytochrome 
p450 oxidase, iNOS, and NADPH) as well as proteins that have metal ions (e.g. Zn, Cu, 
Mn, Fe) incorporated into their structure.43 
 
Carbon Monoxide Releasing Molecules (CORMs)   
 
 One of the limitations in studying carbon monoxide has been its delivery to the 
target.  The majority of in vitro experiments rely on the perfusion of CO for the treatment 
of cells.  Recent work by Motterlini et al. however; has led to the development of 
molecules that can spontaneously release CO.  Carbon monoxide releasing molecules 
(CORMs) are a set of carbonyl compounds containing a central metal ion (i.e. Mn, B, Ru, 
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Fe) designed for the release of CO in tissues.43 Four types of CORMs (CORM-1, -1A, -2, 
and -3) have been developed each with the same function, however differing slightly in 
their structure, solubility and release kinetics.  The prototype CORM-1 (Mn2(CO)10) was 
very constrained in its requirement for photoactivation to release CO.43  Other problems 
arose from its hydrophobic nature, limiting solubility in aqueous media.  CORM-2 is the 
second generation of CORMs to be developed.    This molecule possesses a ruthenium core 
and was hydrophobic like its predecessor.  However unlike CORM-1, CORM-2 is able to 
release CO in an organic solvent depending on ligand displacement by the solvent (i.e. 
DMSO).   The latest forms, CORM-3 and CORM-1A, are the most refined and are more 
compatible with biological systems. Both are water-soluble and release CO by exchanging 
CO for water.  Limitations of CORM-3 include its extremely rapid release and half-life of 
CO; while CORM-1A’s rate of CO release is dependent on pH changes.13,43  Due to its 
relatively recent development, current research surrounding the use of CORMs is very 
limited.  Studies have shown that CORM-2 possesses anti-inflammatory effects in mouse 
lung and human colonic epithelial cells.  These studies suggest that CORM-2 exerts its 
effect through NF-κB and MAPK pathways.27,49  In conclusion, these molecules provide a 
novel approach for the application of CO into biological systems and may provide another 
therapeutic approach to vascular dysfunction, inflammation, tissue ischemia and organ 
rejection.   
 The goal of this study was to determine whether carbon monoxide, a product of 
heme oxygenase-mediated degradation of heme, could influence the expression of heme 
oxygenase-1 in human dermal fibroblasts.  At present, there are no studies that have 
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examined whether any heme oxygenase products can feedback modulate the expression of 
this enzyme.  In addition, the expression and regulation of HO-1 in human dermal 
fibroblasts has not been examined in any detail.  Human dermal fibroblasts play a pivotal 
role in the wound healing and remodeling process. Therefore, modulation of the expression 
of HO-1 by fibroblasts may represent a novel approach for the treatment of problematic 
wounds.  
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Materials and Methods 
 
 
Cells/ Tissue Culture 
 
Human dermal fibroblasts derived from neonatal skin were utilized for these 
studies.  These fibroblasts have been selected because of the ready availability of neonatal 
skin and cells derived from these tissues demonstrate less variability than those derived 
from the adult skin.  The cells utilized were from low passage numbers (no more than 10).  
Cells were cultured in Dulbecco’s modified Eagle’s medium (DMEM), supplemented with 
10% fetal calf serum, 100 U penicillin per ml, and 100mg streptomycin per ml under 5% 
CO2 and at 37°C.  Cells were passaged (1:2) immediately upon becoming confluent. 
 
Harvesting Cells/ Protein Extraction  
 
After treatment and incubation, media was aspirated from the 100mm cell plates.  
Approximately 10ml of 1X PBS was added to the dish and the cells were scraped.  The 
cell/ PBS mixture was then transferred to a centrifuge tube and pelleted by centrifugation 
at 1000 x g for 5 minutes at 4°C.  The PBS was then discarded and the cells were lysed in 
50-100ul of 0.2% SDS-50mM Tris pH 6.8-1mM PMSF.  Cells were then sonicated for 3-5 
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seconds to disrupt chromatin.  Lysates were clarified by centrifugation (15,000 x g for 10 
minutes at 4°C).  Lysates were stored at -80°C until use. 
 
Harvesting Cells/ RNA Extraction 
 
After treatment, media was removed from the cell plates.  Cells were scraped up 
into 10ml of ice-cold 1X PBS.  The cell and PBS mixture was then transferred to a test 
tube and pelleted by centrifugation at 1000 x g for 5 minutes at 4°C.  The PBS was then 
discarded and the cells lysed in 1ml of Tri-reagent.  The mixture was pipetted up and down 
vigorously to ensure shearing of DNA and then transferred to a new tube.  After transfer, 
approximately 200μl of CHCl3 was added.  The mixture was then vortexed and centrifuged 
at 15,000 x g for 15 minutes at 4°C to separate the phases.  The aqueous layer was then 
transferred to a new tube.  An equal amount of isopropanol was added and the nucleic acid 
collected by centrifugation at 15,000 x g for 15 minutes at 4°C.  The isopropanol was then 
removed leaving the pellet inside the tube.  To remove residual DNA and carbohydrates, 
1ml of 2M LiCl (DEPC-treated) was added to the pellet and the solution was vortexed and 
centrifuged (15 x g 15 minutes at 4°C).  The LiCl was then removed and the pellet was 
then washed with 70% ethanol.  After removing the final ethanol wash, the RNA was 
suspended in approximately 25μl of DEPC-treated H2O.  Yields of RNA were calculated 
using Beer’s law: 
 A = e C l 
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where A is the measured absorption at 260 nm, e is the RNA extinction coefficient (25 μl / 
μg / cm), C the RNA concentration and l is the pathlength (1 cm).  Rearrangement of this 
equation yields: 
C = A / (e l) = A * 40 μg/ml 
The actual RNA concentration C(sample) = C(meas) * dilution factor.   Approximately 
50µg of total RNA was a typical yield from a 100mm dish.  The RNA was then stored at    
-80°C until intended use. 
 
CORM-2 Treatments: Dose Response 
 
 
Tricarbonyldichlororuthenium(II) dimer( FW 512) (CORM-2) was used as a source 
for CO.  CORM-2 was dissolved in DMSO to a concentration of 300mM (153 mg/ml). 
Previous research has shown heavy metals to induce the expression of heme oxygenase.43  
Therefore, a control consisting of ruthenium chloride in DMSO was included in most 
experiments.  Due to the relatively short half-life of CORM-2 in DMSO (t1/2=~20 min).  
Care was taken to rapidly serially dilute (half-log dilutions) the CORM-2 after initially 
suspending it in DMSO.  Five 1.5ml tubes were each filled with 400ul of DMSO.  Serial 
dilutions were made by transferring and mixing 200μl (100, 30, 10, 3mM) into the tubes 
containing 400μl DMSO.  10μl each of 300, 100, 30, 10, 3mM CORM-2 solutions were 
added to separate plates for a final concentration of 300, 100, 30, 10, 3μM CORM-2 (0.1% 
DMSO).  Plates were then placed back into the incubator.  After approximately 16-20 
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hours the cells were harvested using the aforementioned protocol.  Immunodetection of 
HO-1 was performed utilizing Western Blotting techniques. 
 
CORM-2 Treatments: Time Course 
 
Eleven confluent plates (100mm) were prepared for each time (0, 15, 30, 45min, 
and 1, 2, 4, 8 , 12, 24, 48 hours).  CORM-2 was dissolved into DMSO to make a 100mM 
(51mg/ml) concentration.  10μl of 100mM CORM-2 was rapidly added to each plate for a 
final concentration of 100μM.  The plates were then placed back into the incubator until 
they were harvested.  Each plate was harvested at a different time corresponding to 0, 15, 
30, 45min, and 1, 2, 4, 8, 12, 24, 48 hours time points.  Immunodetection of HO-1 was 
performed utilizing Western Blotting techniques.  
 
 
 
Inhibitor Experiments 
 
 
Eleven confluent cell plates (100mm) were prepared for this experiment.  Inhibitors 
for the JNK, PI3K, MAPK, cGMP, tyrosine kinase, and PKC pathways were utilized 
(Table 1).  Previous research in our laboratory has demonstrated the effectiveness of these 
inhibitors in human dermal fibroblasts. The inhibitor IC50  values were tripled to produce 
an inhibitor concentration that insured blockage of the pathway (Table 2).  First each 
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inhibitor plate was pretreated with the specific inhibitor for approximately 2-3 hours.  This 
allowed the inhibitors to begin working before the CORM-2 was added.  After 
pretreatment, approximately 50-100mg of CORM-2 was weighed out and dissolved into 
DMSO to make a 100mM (51mg/ml) concentration.  Since the half-life of the CORM-2 is 
so short (approximately 20 min) it is important to quickly perform the next few steps.  The 
CORM-2 was then rapidly suspended into DMSO to 100mM.  10μl of 100mM CORM-2 
was added to each of the inhibitor plates for a final concentration of 100μM.  CORM-2 
was also added to one other plate as a CORM-2 only control.  Other controls included a 
DMSO plate, a 100μM RUCL plate, a no treatment plate, and a reverse order CORM-2 
plate.  The reverse order CORM-2 was prepared by driving out the CO in the CORM-2 
solution by bubbling nitrogen for 10 seconds. After treatment the plates were then placed 
back into the incubator until they were harvested.  Immunodetection of HO-1 was 
performed utilizing Western Blotting techniques. 
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Table 1:  Inhibitor treatments. 
Plate Treatment Final Conc. Pretreatment CORM-2 applied
1 No treatment    
2 DMSO treated    
3 Reverse Order    
4 RuCl 100uM   
5 CORM-2 only 100uM  x 
6 ODQ 20nM x x 
7 U0126 250nM x x 
8 LY294002 4.2uM x x 
9 SB202190 1uM x x 
10 SP600125 300nM x x 
11 Herbimycin A 2700nM x x 
12 Calphostin C 150nM x x 
13 Genistein 7.8uM x x 
  
 
Table 2:  Agonist and inhibitors utilized. (Calbiochem) 
 
Inhibitor Name Pathway IC50 
ODQ cGMP 20nM 
U0126 Mek/Mapk 72nM 
LY294002 PI3K 1.4uM 
SB202190 p38/Mapk 280nM 
SP600125 JNK-2  90nM 
Herbimycin A Tyr Kinase 900nM 
Calphostin C PKC 50nM 
Genistein Tyr Kinase 2.6uM 
   
Agonist Name   
YC-1 cGMP 300nM 
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Micro-BCA Protein Assay  
 
 
 
Protein concentrations of samples were measured utilizing the Pierce Micro-
Bicinchoninic acid (BCA) protein assay kit according to Smith et al.46  The peptide bonds 
of protein interact with alkaline Cu2+  to form a tetradentate- Cu1+ complex.  Bicinchoninic 
acid is a water-soluble sodium salt that binds to the cuprous (Cu1+) ion to form a purple 
color.46  Greater protein concentrations in the sample result in a proportionally more 
intense purple color.   3μl of the protein sample and 97μl dH2O were pipetted into a 96 
well dish for a volume of 100μl. Bovine Serum Albumin (BSA) (1mg/ml) was used as the 
protein for the standards.  The concentrations of BSA gradually increased from well one 
(no BSA) to well eight (24μl BSA).  The standards were prepared by first pipetting 
decreasing volumes of dH2O into 8 wells (97, 95, 93, 89, 85, 81, 77, 73μl).  Next 
increasing volumes of BSA were added to each of the standard wells except the first one 
(0, 2, 4, 8, 12, 16, 20, 24μl).  3μl of vehicle was then added to each of the standard wells 
for a final volume of 100μl.  Vehicle represents the buffer/solution in which the protein 
sample is harvested and stored.  Most cell lysis buffers contain detergents that can alter the 
color response of this assay.  To compensate for this, equivalent amounts of the solution 
that the sample is in were added to the BSA standards.  100μl of working reagent was 
added to the standards and samples for a final volume of 200μl.  Each well was mixed and 
the bubbles were removed from each well.  Wells containing protein will develop a purple 
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color.  A Bio-Tek plate reader at a wavelength of 562nm then read the absorbance for 
approximately 20-30 minutes.  It may be necessary to develop for a longer period for more 
dilute samples.  Concentrations and standard curves were then calculated and analyzed. 
 
 
Immunodetection of Heme Oxygenase 
 
 
 
After protein concentrations were determined using the BCA assay, Western 
Blotting techniques were utilized for the immunodetection of HO-1.  Approximately 60ug 
of protein sample was diluted in dH2O for a volume of 30ul.  To this, 6μl of reducing 
Laemmli buffer (as above, but with 900mM 1,4-dithiothreitol) was added.  Samples were 
heated for five minutes at 95°C, loaded onto a 10% SDS-PAGE gel, and then run at 150 V 
for approximately one hour.  After electrophoresis the gel was transferred to nitrocellulose 
or PVDF (Polyvinylidene Fluoride Transfer Membrane) membrane based on the Towbin 
method.52  Ten ml of 10x electroblot buffer (250mM Tris, 1.92M Glycine) was diluted 
with deionized water to a 1x solution.   The transfer cassette and nitrocellulose were 
assembled while submerged in a pyrex dish containing the electroblot buffer to avoid 
trapping bubbles in the cassette.  Buffer was poured into an electrophoresis chamber along 
with a cooling insert, a small stirring bar, and the cassette.  The apparatus was mounted on 
a magnetic stirrer to facilitate buffer circulation, and transfer was initiated at maximum 
current (400mA, Bio-Rad Power Pac 300) for approximately one hour.  The apparatus was 
removed and the gel was traced along the nitrocellulose with a soft #2 pencil.  Pre-stained 
markers were also outlined. 
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The nitrocellulose was then set for immunodetection.  The membrane was placed in 
20ml TBST blocking solution (20mM Tris, 137mM NaCl, 0.1%Tween, pH to 7.6 with 
HCl) containing 5% nonfat dried milk, positioned on a rocking table, and incubated at 
room temperature for 3 hours.  Primary antibodies (Rabbit Anti-HO-1 Polyclonal, 
Stressgen) were diluted 1000:1 in 20ml of TBST containing 1% BSA, then applied to 
membranes and incubated overnight with rocking at 4°C.  Primary solution was then 
removed and the membranes were washed four times with 30ml of TBST for 10 minutes 
each.   The secondary antibody (Anti-Rabbit IgG horseradish peroxidase-linked, 
Amersham) was diluted 10,000:1 in 20 ml of TBST and applied to the gels, incubating at 
room temperature with rocking for one hour.  The solution was discarded and the 
membranes washed four times in TBST for 10 minutes each.  During the final wash, 
equivalent amounts (5ml each) of Enhanced Luminol Reagent and Oxidizing Reagent 
(Western Lighting Chemiluminescence Reagent Plus, PerkinElmer Life Sciences) were 
prepared.  Membranes were placed in chemiluminescent reagent for 1 minute each, then 
wrapped in Saran Wrap (Kroger, OH) and sealed.  In the darkroom, several exposures were 
made at varying durations (1”, 10”, 60”) on Kodak X-Omat AR film. 
 
 
Cyclic GMP experiment 
 
 
Six confluent cell plates were prepared for this experiment.  The first three plates 
served as the controls for this experiment (Plate one was not treated, plate two was DMSO 
treated, and plate three was CORM-2 only.)   
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1. Control: no treatment 
2. DMSO only 
3. CORM-2 only 
4. CORM-2 and YC-1  
5. CORM-2, YC-1 and ODQ 
6. CORM-2 and ODQ 
 
First the cGMP inhibitor (ODQ) was diluted to a concentration of 20μM (3X IC50).  The 
cGMP agonist (YC-1, Calbiochem) was then diluted to 300nM.    Plates #3, 4, 5 were 
pretreated for 2-3 hours with inhibitor, agonist, or inhibitor and agonist.  After 
pretreatment, approximately 50-100mg of CORM-2 was weighed out and dissolved into 
DMSO to make a 100mM (51mg/ml) concentration.  The CORM-2 was then rapidly 
suspended into DMSO to 100mM.  10μl of 100mM CORM-2 was then added to plates #2, 
3, 4, and 5.  DMSO was then added to plate six.  After treatment the plates were then 
placed back into the incubator until they were harvested.  Immunodetection of HO-1 was 
performed utilizing Western Blotting techniques. 
 
 
Statistical Analysis 
 
 
Western blot images were scanned with SigmaScan software and densitometrically scored.  
Values were recorded and presented as functions of volume, which was computed as 
average intensity x area of the protein bands.  
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Results 
 
BCA assay/ Protein Quantification 
The standard curves for all protein samples were very accurate.  Each assay 
produced an R2 value of .95 or greater (perfect score when R2 =1).  As a result we were 
confident of the amount and concentration of our protein samples.  Protein concentrations 
usually ranged from 3 to 10μg/μl depending on the amount of buffer added to the protein 
in the last step of harvesting.   
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A. 
 
 
 
 
 
B. 
 
 
 
 
 
 
 
 
Figure 2.  Standard curves generated for A) dose response and B) time-course 
experiments. 
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HO-1 Immunoblots 
 
1.  Dose Response 
 
The purpose of this experiment was to determine if CORM-2 would induce heme 
oxygenase as well as to determine which CORM-2 concentration would produce the 
strongest expression.  Western blot analysis demonstrated that incubation with CORM-2 
induced the expression of heme oxygenase-1.  Different concentrations of CORM-2 (0, 10, 
30, 100, 300μM) were correlated with increased expression of heme oxygenase-1.  The 
peak HO-1 expression occurred at 100μM and began to decrease at larger concentrations.    
Previous research has shown heavy metals to induce the expression heme oxygenase.43  
Therefore, a control consisting of ruthenium chloride in DMSO was included in most 
experiments.  A DMSO only treated plate served as another control.  Controls did not 
induce HO-1 expression. 
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Figure 3.  Carbon Monoxide induced heme oxygenase-1 expression in dermal fibroblasts.  
Fibroblasts were incubated with different concentrations of carbon monoxide donor, 
CORM-2.  After approximately 16 hours, HO-1 expression was assessed by immunoblot 
analysis.  Lanes: 1) untreated cells; 2) DMSO only; 3) 100μM Ruthenium(III) chloride 
hydrate; 4-7) 10, 30, 100, 300μM CORM-2. 
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2.  Time-course 
 
The purpose of this experiment was to determine the time response of HO-1 to 
CORM-2 induction.  From the previous dose response assay, it was determined that 
maximum HO-1 expression occurred with 100μM CORM-2.  Western blot analysis 
demonstrated that heme oxygenase-1 expression increased gradually over time.  It was 
determined that heme oxygenase expression peaked around 16 hours.  Longer treatments 
resulted in decreased expression.  Controls, ruthenium(III) chloride hydrate and DMSO 
treated cells, failed to induce HO-1. 
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Figure 4.  Time-course induction of heme oxygenase-1 by CORM-2.  Fibroblasts were 
incubated with 100μM CORM-2.  Samples were harvested at different time points ranging 
from 0 minutes to 48 hours.  Once harvested, HO-1 expression was assessed by 
immunoblot analysis.  Lanes: 1) 0 min; 2) 15 min; 3) 30 min; 4) 45 min; 5-11) 1, ,2 , 4, 8, 
12, 24, 48 hr respectively. 
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3.  Inhibitor experiments 
 
The purpose of this experiment was to identify the mechanism for the induction of 
HO-1 by CORM-2.  Well-characterized inhibitors of various signaling pathways were used 
(Table 1).  These include an inhibitor of ERK (U0126 ); p38 (SB202190 )(Cells were 
pretreated with a three-fold higher concentration of the reported IC50 for each inhibitor.  
Cells pretreated with inhibitors for JNK-2, p38/p42/MEK MAPK, PI3K, cGMP pathways 
resulted in no change of heme oxygenase-1 expression after treatment with CORM-2.  
Inhibition of PKC and tyrosine kinase pathways by calphostin C, genistein, and 
herbimycin A did not alter expression.   
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Figure 5.  Effect of JNK-2, PI3K, p38/ MEK MAPK, cGMP inhibitors on CO induction of 
HO-1 in dermal fibroblasts.  Fibroblasts were pretreated for 2-3 hours with inhibitors and 
then treated with 100μM CORM-2 (lanes 1-5, 7, and 9).  After approximately 16 hours, 
cells were harvested and HO-1 expression was assessed utilizing immunoblot analysis.  
Lanes: 1) LY294002 (3μM); 2) SB202190 (1μM); 3) SP600125 (300nM); 4) U0126 
(260μM); 5) ODQ (20μM); 6) DMSO only; 7) untreated cells; 8) CORM-2 only; 9) 
Ruthenium(III) chloride hydrate (100μM). 
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Figure 6.  Effect of PKC and Tyrosine kinase inhibitors on CO induction of HO-1 in 
dermal fibroblasts.  Fibroblasts were pretreated for 2-3 hours with inhibitors and then 
treated with 100μM CORM-2 (lanes1-4).  After approximately 16 hours, cells were 
harvested and HO-1 expression was assessed utilizing immunoblot analysis.  Lanes: 1) 
Genistein (7.8nM); 2) Calphostin C (150nM); 3) Herbimycin A (2.7μM); 4) 100μM 
CORM-2 only; 5) Ruthenium Chloride hydrate (100μM); 6) DMSO only; 7) untreated 
cells. 
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4.  Cyclic GMP 
 
The purpose of this experiment was to determine if a cGMP agonist would induce 
HO-1.  Western blot analysis demonstrated that treatment of fibroblasts with ODQ, a 
cGMP inhibitor, did not block or attenuate HO-1 expression.  It was also shown that 
treatment with YC-1, a cGMP agonist, did not turn on HO-1.  These data suggest that CO-
induction of heme oxygenase-1 by CORM-2 operates through a pathway that is 
independent of cGMP.   
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Figure 7.  Cyclic GMP did not induce heme oxygenase-1 expression in dermal fibroblasts.  
Fibroblasts were pretreated with YC-1 and ODQ, a cGMP agonist and inhibitor, and then 
incubated with CORM-2.  After approximately 16 hours, cells were harvested and HO-1 
expression was assessed utilizing immunoblot analysis.  Lanes: 1) CORM-2 only; 2) 
untreated cells; 3) DMSO only; 4) CORM-2 and YC-1; 5) YC-1 only; 6) CORM-2 and 
ODQ. 
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mechanism for the prevention of heme depletion.  We initially speculated that in similarly 
dermal-derived fibroblasts, CO would act as a feedback inhibitor of HO-1 expression.  
However, data obtained in this study provide a strong indication that CO released via 
CORM-2 is an efficient inducer of HO-1 expression.    The absence of a similar induction 
using ruthenium chloride or DMSO only suggests that this response is likely due to that of 
CO and not to the heavy metal moiety of the tricarbonyldichlororuthenium(II) dimer or to 
the DMSO vehicle.  Whether CO supplied as a gas elicits the same response remains to be 
tested. 
Dose response experiments revealed that CORM-2 CO induced the expression of 
HO-1 with maximum expression occurring at 100µM.  Time-course experiments revealed 
that maximum HO-1 expression occurred between 12 and 24 hours after treatment with 
100μM CORM-2.   
 Our next aim was to begin identifying the signaling pathway or pathways involved 
in CO induction of HO-1.  Other studies have indicated that CO exerts its effects through a 
multitude of pathways, with MAPK and soluble guanylyl cyclase (sGC) being the 
predominant cascades (Figure 8).43   As a result, it was our hypothesis that the CO released 
from CORM-2 would most likely act through one of these major pathways.  To test this 
hypothesis, inhibitor experiments were conducted.  Inhibitors utilized included those for 
sGC, MAPK (p38, JNK-II, ERK) pathways as well as those for tyrosine kinase, and PKC 
cascades.  Pretreatment with inhibitors permitted sufficient time for the inhibitors to enter 
the cells.    Inhibitor concentrations applied to the cells were triple the IC50 to increase the 
likelihood of inhibition without inducing undue secondary inhibition of other kinases or 
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causing unacceptable levels of cell death.  Somewhat surprisingly, our data suggests no 
relationship between these pathways and induction of HO-1 by CORM-2. Controls for this 
experiment included untreated, DMSO, and RuCl treated plates.  These controls showed no 
increase in HO-1 expression.   
Because much of the literature supports a role for guanylate cyclase mediating CO 
signaling, the ability of a cGMP agonist43, YC-1, to induce the expression of HO-1 was 
tested.  YC-1 treated cells did not show any significant induction of HO-1 protein. 
Blockage of the cGMP pathway also did not attenuate CO-induction of HO-1.  These 
results support the previous data indicating that CORM-2 operates through a cGMP-
independent pathway.  Interestingly, cells treated with ODQ and CORM-2 seemed to 
potentiate HO-1 expression.  Similar results were reported in experiments with CORM-3 
and ODQ in human platelets.6   This suggests that the action of CO might be accentuated 
by the removal of the sGC function.  The mechanism and physiological meaning of these 
findings remain to be determined. 
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Figure 8.  Signaling pathways for carbon monoxide. 
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Future Perspectives 
It seems unlikely that gaseous CO and CO released from CORM-2 are chemically 
distinct entities.  Therefore the most plausible explanation is that the CO released from 
CORM-2 reaches different targets.  Apart from the pathways tested, other studies have 
demonstrated that CO can act through the modulation of NF-kappaB/IkB molecules.27,49 
Therefore blockage of this pathway might provide some insight into the mechanism 
responsible for the induction of HO-1 by CORM-2.  CO has a high affinity and readily 
binds to metal ions.43   Therefore binding of CO to the metal ions present in some proteins 
might be another mechanism by which HO-1 is induced.  In our experiments we utilized 
the second-generation CORM-2 molecule that incorporates the heavy metal ruthenium into 
its structure.  Although the ruthenium chloride control did not show an increase in HO-1 
expression, future studies should utilize CORM-1A.  Use of this molecule would 
effectively reduce the chance that the effects of CORM-2 on HO-1 expression are a result 
of heavy metal stimulation.  CORM-1A is also more soluble in aqueous environments 
allowing for more efficient diffusion of CO into the media and onto the cells.   
Although the exact mechanism remains to be elucidated, the results of this study 
may have important implications.  It is surprising that CO, a product of heme degradation, 
released from CORM-2 actually increases the expression of HO-1 in human dermal 
fibroblasts.  This may serve as a mechanism to amplify heme oxygenase expression in 
stressed tissue. In contrast to higher levels, lower levels of CO possess beneficial 
characteristics.  In certain epithelial cell lines and in models for post-ischemic myocardial 
46 
injury, CORMs have already been demonstrated to show beneficial characteristics.27,55   As 
a result, there might be possible therapeutic applications of CORM-2 due to its induction 
of HO-1 and associated cytoprotective effects.  CORMs may provide a method by which 
local application may be beneficial as opposed to systemic CO which is harmful.   
Although a significant amount of research has been performed on chronic wounds, 
we still have very limited understanding of the pathophysiology behind the development 
and maintenance of these lesions.  Therefore by elucidating the mechanism by which HO-1 
is expressed in these cells, future research might be able to develop more effective 
therapeutic approaches for the treatment of chronic wounds. 
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